[Pharmacokinetic study of a cephalosporin, cefoperazone, in liver failure].
The pharmacokinetics of cefoperazone, a semi-synthetic cephalosporin for parenteral use with a spectrum covering P. aeruginosa, E. cloacae, indole-positive Proteus and S. Marcescens, was studied after a 2-h intravenous infusion of 2 g of the drug in 6 patients with moderate liver function impairment (viral hepatitis in 4 cases, alcoholic fatty liver and cirrhosis in 2 cases). At the end of the infusion, mean serum concentrations (determined by a bioassay) were 208 microgram/ml in the patients and 134 microgram/ml in healthy volunteers. The half-life was 4.3 h in patients and 1.6 h in healthy volunteers. Volume of distribution and renal clearance were similar in the two groups. Extrarenal clearance of cefoperazone was lower in the patients (7.3 ml/min) than in the control group (59.4 mg/min). Urinary excretion of biologically active drug was markedly increased in the patients (79% of the dose) compared with healthy volunteers (24%). This study provides evidence that liver function impairment increases with both the apparent half-life of elimination and the urinary excretion of the drug. The results raise the question of the desirability of cefoperazone dosage adjustment in patients with hepatic diseases.
D000328:Adult; D002438:Cefoperazone; D002511:Cephalosporins / Q000097:blood*; D005235:Fatty Liver, Alcoholic / Q000097:blood; D005260:Female; D006506:Hepatitis A / Q000097:blood; D006509:Hepatitis B / Q000097:blood; D006526:Hepatitis C / Q000097:blood; D006801:Humans; D007700:Kinetics; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood; D008107:Liver Diseases / Q000097:blood*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged
D002511:Cephalosporins; D002438:Cefoperazone
Etude pharmacocinétique d'une céphalosporine, la céfopérazone, dans l'insuffisance hépatique.